Reporting to the Chief Medical Officer, the Senior Director will own and be accountable for global regulatory strategy and execution from Phase 1/2 development through registrational planning in the U.S., EU, UK, and support activities in Asia-Pacific, partnering closely with Clinical Development, Clinical Operations, CMC, Quality, and external regulatory partners. Provide strategic regulatory guidance on early clinical development, including positioning Phase 1 programs for successful Phase 2 development and expedited programs, designations, and approval pathways (e.g., Fast Track, Breakthrough Therapy, Orphan Drug, PRIME, Accelerated Approval).